PPI Efficacy Studies In Certain Infants May Be Needed, Cmte. Says
Executive Summary
Proton pump inhibitor efficacy studies in certain infants under one year of age may be needed, members of FDA's Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee generally agreed at its June 11 meeting
You may also be interested in...
Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says
FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.
Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says
FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.
PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic
In this instance, FDA seems more interested than the sponsors in a potential market expansion.